Dn B Asset Management As Neurocrine Biosciences Inc Transaction History

Dn B Asset Management As

$21.2 Billion
Q1 2025

A detailed history of Dn B Asset Management As transactions in Neurocrine Biosciences Inc stock. As of the latest transaction made, Dn B Asset Management As holds 128,112 shares of NBIX stock, worth $16 Million. This represents 0.07% of its overall portfolio holdings.

Number of Shares

128,112

Previous 118,227 8.36%

Holding current value

$16 Million

Previous $16.1 Million 12.2%

% of portfolio

0.07%

Previous 0.07%

21 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2025 May 15, 2025	BUY	$107.22 - $153.29 $1.06 Million - $1.52 Million	9,885 Added 8.36%	128,112 $14.2 Million
Q4 2024 Feb 12, 2025	BUY	$111.62 - $139.44 $390,670 - $488,040	3,500 Added 3.05%	118,227 $16.1 Million
Q3 2024 Nov 12, 2024	BUY	$114.58 - $153.15 $4.56 Million - $6.09 Million	39,781 Added 53.08%	114,727 $13.2 Million
Q2 2024 Jul 05, 2024	BUY	$130.86 - $143.19 $1.44 Million - $1.57 Million	10,998 Added 17.2%	74,946 $10.3 Million
Q1 2024 Apr 12, 2024	SELL	$130.4 - $143.74 $247,108 - $272,387	-1,895 Reduced 2.88%	63,948 $8.82 Million
Q4 2023 Jan 04, 2024	SELL	$106.07 - $132.76 $1.51 Million - $1.88 Million	-14,189 Reduced 17.73%	65,843 $8.68 Million
Q3 2023 Oct 13, 2023	SELL	$94.02 - $117.1 $342,702 - $426,829	-3,645 Reduced 4.36%	80,032 $9 Million
Q2 2023 Jul 06, 2023	SELL	$89.53 - $104.87 $1.11 Million - $1.3 Million	-12,440 Reduced 12.94%	83,677 $7.89 Million
Q1 2023 Apr 20, 2023	BUY	$94.11 - $123.02 $889,904 - $1.16 Million	9,456 Added 10.91%	96,117 $9.73 Million
Q4 2022 Jan 12, 2023	SELL	$106.72 - $127.06 $117,925 - $140,401	-1,105 Reduced 1.26%	86,661 $10.4 Billion
Q3 2022 Oct 11, 2022	SELL	$92.03 - $107.81 $3.55 Million - $4.16 Million	-38,559 Reduced 30.52%	87,766 $9.32 Million
Q2 2022 Jul 08, 2022	SELL	$75.79 - $100.07 $669,149 - $883,518	-8,829 Reduced 6.53%	126,325 $12.3 Billion
Q1 2022 Apr 08, 2022	SELL	$72.45 - $94.81 $396,229 - $518,515	-5,469 Reduced 3.89%	135,154 $12.7 Million
Q4 2021 Jan 12, 2022	BUY	$79.65 - $106.22 $1.78 Million - $2.37 Million	22,344 Added 18.89%	140,623 $12 Million
Q3 2021 Oct 15, 2021	SELL	$86.18 - $99.03 $1.72 Million - $1.98 Million	-19,944 Reduced 14.43%	118,279 $11.3 Million
Q2 2021 Jul 06, 2021	BUY	$89.43 - $102.27 $1.74 Million - $1.99 Million	19,454 Added 16.38%	138,223 $13.5 Billion
Q1 2021 Apr 15, 2021	BUY	$87.57 - $119.4 $7.32 Million - $9.98 Million	83,562 Added 237.34%	118,769 $11.6 Million
Q4 2020 Jan 19, 2021	BUY	$86.91 - $108.33 $1.98 Million - $2.47 Million	22,831 Added 184.48%	35,207 $3.37 Million
Q2 2020 Jul 08, 2020	BUY	$85.09 - $130.36 $125,677 - $192,541	1,477 Added 13.55%	12,376 $1.51 Billion
Q1 2020 Apr 17, 2020	SELL	$75.11 - $113.76 $69,852 - $105,796	-930 Reduced 7.86%	10,899 $943,000
Q4 2019 Jan 13, 2020	BUY	$86.8 - $118.57 $1.03 Million - $1.4 Million	11,829 New	11,829 $1.27 Million

Others Institutions Holding NBIX

# of Institutions

650

Shares Held

97.2M

Call Options Held

749K

Put Options Held

553K

View Full List

About NEUROCRINE BIOSCIENCES INC

Ticker NBIX
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 95,639,296
Market Cap $11.9B
Description
Neurocrine Biosciences, Inc. discovers, develops, and markets pharmaceuticals for neurological, endocrine, and psychiatric disorders. The company's portfolio includes treatments for tardive dyskinesia, Parkinson's disease, endometriosis, and uterine fibroids, as well as clinical programs in various therapeutic areas. Its lead asset is INGREZZA, ...

More about NBIX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Dn B Asset Management As, based on Form 13F filings with the SEC.

News

Stay updated on Dn B Asset Management As with notifications on news.

Account

Dn B Asset Management As Neurocrine Biosciences Inc Transaction History